2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 41920902.
- Also identified by DOI 10.1093/cid/ciaf680.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This article provides a focused update to the clinical practice guideline on the treatment and management of people with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents 9 updated recommendations on the use of nirmatrelvir/ritonavir, remdesivir, and molnupiravir, in adults with mild to moderate COVID-19. The recommendations are based on evidence derived from a systematic literature review and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. The panel also provides a section on how to apply these recommendations, including an algorithm on the selection of antivirals.